These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 21964704

  • 1. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
    Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T.
    Clin Exp Nephrol; 2012 Apr; 16(2):310-5. PubMed ID: 21964704
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
    Turan N, Benekli M, Ozturk SC, Inal S, Memis L, Guz G, Cetin B, Buyukberber S.
    Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
    [Abstract] [Full Text] [Related]

  • 3. Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.
    Quintyne KI, Neenan T, Casserly L, Gupta R.
    BMJ Case Rep; 2014 May 28; 2014():. PubMed ID: 24872478
    [Abstract] [Full Text] [Related]

  • 4. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR, Yhim HY, Yim CY, Kwak JY, Song EK.
    Ann Pharmacother; 2011 Oct 28; 45(10):e56. PubMed ID: 21954449
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
    Mutlu H, Büyükçelik A, Akça Z, Kaya N.
    J Oncol Pharm Pract; 2014 Aug 28; 20(4):298-301. PubMed ID: 23929730
    [Abstract] [Full Text] [Related]

  • 6. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
    Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noël LH, Knebelmann B.
    Nephrol Dial Transplant; 2009 Feb 28; 24(2):682-5. PubMed ID: 19054798
    [Abstract] [Full Text] [Related]

  • 7. The case / progressive hypertension and proteinuria on anti-angiogenic therapy.
    Obhrai JS, Patel TV, Humphreys BD.
    Kidney Int; 2008 Sep 28; 74(5):685-6. PubMed ID: 18709027
    [No Abstract] [Full Text] [Related]

  • 8. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR, Leggas M.
    Clin Ther; 2007 Jul 28; 29(7):1338-53. PubMed ID: 17825686
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
    Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R.
    Nephrol Dial Transplant; 2010 Mar 28; 25(3):1001-3. PubMed ID: 20019017
    [Abstract] [Full Text] [Related]

  • 10. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
    Saylor PJ, Reid TR.
    J Clin Oncol; 2007 Aug 10; 25(23):3544-6. PubMed ID: 17687160
    [No Abstract] [Full Text] [Related]

  • 11. Guillain-Barré syndrome after treatment with sunitinib malate?
    Mulherin B, Loconte NK, Holen KD.
    Oncology (Williston Park); 2008 Jan 10; 22(1):66-7, 70-1. PubMed ID: 18251284
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
    George S.
    Curr Oncol Rep; 2007 Jul 10; 9(4):323-7. PubMed ID: 17588358
    [Abstract] [Full Text] [Related]

  • 14. Sunitinib-induced endocapillary proliferative glomerulonephritis with IgA2 deposit in addition to thrombotic microangiopathy: a case report.
    Zhang X, Wang H, Li J, Zhou F, Zhao M, Su T.
    BMC Nephrol; 2024 Aug 30; 25(1):284. PubMed ID: 39215250
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.
    Liu YC, Chang PM, Liu CY, Yang CY, Chen MH, Pan CC, Chen MH.
    Jpn J Clin Oncol; 2011 Nov 30; 41(11):1277-81. PubMed ID: 21965162
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report.
    Ko HC, Lee HP, Wu JD, Ma TL, Shen CH, Lin CT, Cheng MC, Jou YC.
    BMC Nephrol; 2022 Apr 18; 23(1):150. PubMed ID: 35436872
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
    Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH.
    Lancet; 2007 Dec 15; 370(9604):2011-9. PubMed ID: 18083403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.